Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,464 total articles

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Arcutis Biotherapeutics announces publication of a new expert consensus manuscript in the American Journal of Clinical Dermatology offering age-specific guidance for diagnosis and management of genital psoriasis across pediatric, adult, and older populations. The paper promotes routine genital assessment, empathetic communication, and individualize…

RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

RadNet, Inc., a leading US outpatient diagnostic imaging provider, announced its intention to secure a $200 million incremental term loan. This funding aims to support future acquisitions, organic expansion, health system partnerships, and other corporate purposes to accelerate strategic growth across its national imaging network and technology pla…

Diginex Provides Update on Proposed Resulticks Acquisition

Diginex Provides Update on Proposed Resulticks Acquisition

Diginex Limited announced the extension of the long stop date to June 12, 2026 for its proposed acquisition of Resulticks Global Companies Pte. Limited. The acquisition aims to significantly expand Diginex's platform by integrating ESG data with real-time decisioning and customer engagement capabilities. Resulticks is expected to bring approximatel…

WTW receives DFSA licence approval to operate investment business in Dubai International Financial Centre (DIFC)

WTW receives DFSA licence approval to operate investment business in Dubai International Financial Centre (DIFC)

WTW (NASDAQ: WTW), a global advisory and solutions firm, has received approval from the Dubai Financial Services Authority to operate as WTW Investments (DIFC) Limited in Dubai International Financial Centre. This licence enables WTW to offer regulated investment advisory services and fund solutions locally, marking a strategic expansion in the gro…

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NewAmsterdam Pharma announced multiple presentations at the National Lipid Association 2026 Scientific Sessions showcasing data on obicetrapib, their novel oral low-dose CETP inhibitor for hypercholesterolemia treatment. The presentations cover efficacy, safety, and potential cardiovascular benefits based on extensive Phase 2 and 3 clinical trials.…

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to advance conditionally activated bispecific immunotherapies utilizing CytomX's PROBODY platform and Regeneron's Veloci-Bi technology. The expanded deal includes a $37 million target selection payment and potential milestones totaling approximately $4 billion as Rege…

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Spyre Therapeutics has completed enrollment for all sub-studies in its SKYWAY basket trial evaluating SPY072, an anti-TL1A antibody, across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The company reaffirms expected clinical data readouts in Q3 2026 for RA and Q4 2026 for PsA and axSpA, supporting poten…

Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST),Westwood Salient Enhanced Energy Income ETF (WEEI) and Westwood Enhanced Income Opportunity (YLDW)

Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST),Westwood Salient Enhanced Energy Income ETF (WEEI) and Westwood Enhanced Income Opportunity (YLDW)

Westwood Holdings Group (NYSE: WHG) disclosed monthly income distributions for three ETFs—Westwood Salient Enhanced Midstream Income ETF (MDST), Westwood Salient Enhanced Energy Income ETF (WEEI), and Westwood Enhanced Income Opportunity (YLDW). These actively managed funds provide monthly income through a combination of dividends and covered call …

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics announced updated data from the Phase 1 portion of its COMPARE trial evaluating mivocabtagene autoleucel (miv-cel) in patients with active ACPA-positive, treatment-refractory rheumatoid arthritis. The data demonstrated deep B-cell depletion, sustained reduction in disease-associated autoantibodies, substantial reduction in dise…

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion announces a new research collaboration with the University of Leicester to evaluate the combination of its investigational menin inhibitor, icovamenib, with semaglutide in overweight and obese individuals. This randomized double-blind study aims to determine if icovamenib can enhance weight loss while preserving lean mass and improvin…

Grayscale Investments Launches the Lowest Gross Fee Hyperliquid ETP in the U.S. with Grayscale® Hyperliquid Staking ETF (Ticker: HYPG)

Grayscale Investments Launches the Lowest Gross Fee Hyperliquid ETP in the U.S. with Grayscale® Hyperliquid Staking ETF (Ticker: HYPG)

Grayscale Investments has introduced the Grayscale Hyperliquid Staking ETF (HYPG) on Nasdaq, providing investors with exposure to the HYPE token of the Hyperliquid protocol along with staking rewards. As the lowest gross fee Hyperliquid ETP in the US, HYPG aims to offer a cost-efficient way to invest in a rapidly growing decentralized finance ecosy…

Richtech Robotics Completes Strategic Acquisition of Warehouse Facility in Las Vegas to Accommodate Robotics and AI Powered Growth Objectives

Richtech Robotics Completes Strategic Acquisition of Warehouse Facility in Las Vegas to Accommodate Robotics and AI Powered Growth Objectives

Richtech Robotics Inc., listed on Nasdaq as RR, has completed the acquisition of a 79,325 square foot warehouse facility in Las Vegas for $21.2 million. This expansion is aimed at enhancing the company's AI infrastructure and robotics development, supporting its Industrial, Commercial, and Data Services strategic pillars. The facility will house GP…

Twin Disc to Present at Three Part Advisors Ideas Conference

Twin Disc to Present at Three Part Advisors Ideas Conference

Twin Disc, Inc., a manufacturer of marine and heavy-duty off-highway power transmission equipment, announced that its CFO Jeff Knutson will present at the Three Part Advisors East Coast IDEAS Conference on June 10, 2026, in New York. The company also offers one-on-one investor meetings at the event, aiming to engage with institutional investors and…

Rent the Runway, Inc. Announces First Quarter 2026 Results

Rent the Runway, Inc. Announces First Quarter 2026 Results

Rent the Runway, Inc. announced its Q1 fiscal 2026 results, achieving $89.9 million in revenue, up 29.2% year-over-year, exceeding guidance. The company showed improvement in EBITDA margin and add-on revenue increased by 70.4% YoY. New interim leadership appointments were made, and the company highlighted AI-driven personalization enhancements to i…

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Inc., a US-based regenerative and cellular medicine company, announced the appointment of Rick Gonzalez as Chief Commercial Officer. Gonzalez brings extensive leadership experience in biotechnology and healthcare commercialization, supporting Celularity's efforts to advance its placental-derived cellular therapies, including cenplacel-L …

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Biogen announced presentations of 14 abstracts highlighting clinical data from its nephrology portfolio, including approved drug EMPAVELI (pegcetacoplan) and the investigational anti-CD38 antibody felzartamab, at the European Renal Association and American Transplant Congresses. The data show sustained efficacy and safety in treating rare kidney di…

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics has completed enrollment of 71 participants in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial evaluating z-basivarsen (DYNE-101) for treatment of myotonic dystrophy type 1 (DM1). Topline data are anticipated in Q1 2027, supporting a potential U.S. Accelerated Approval submission by Q3 2027 and possible launch i…